Feasibility of 18F-Fluoromisonidazole Kinetic Modeling in Head and Neck Cancer Using Shortened Acquisition Times

18F-fluoromisonidazole dynamic PET (dPET) is used to identify tumor hypoxia noninvasively. Its routine clinical implementation, however, has been hampered by the long acquisition times required. We investigated the feasibility of kinetic modeling using shortened acquisition times in 18F-fluoromisonidazole dPET, with the goal of expediting the clinical implementation of 18F-fluoromisonidazole dPET protocols. Methods: Six patients with squamous cell carcinoma of the head and neck and 10 HT29 colorectal carcinoma–bearing nude rats were studied. In addition to an 18F-FDG PET scan, each patient underwent a 45-min 18F-fluoromisonidazole dPET scan, followed by 10-min acquisitions at 96 ± 4 and 163 ± 17 min after injection. Ninety-minute 18F-fluoromisonidazole dPET scans were acquired in animals. Intratumor voxels were classified into 4 clusters based on their kinetic behavior using k-means clustering. Kinetic modeling was performed using the foregoing full datasets (FD) and repeated for each of 2 shortened datasets corresponding to the first approximately 100 min (SD1; patients only) or the first 45 min (SD2) of dPET data. The kinetic rate constants (KRCs) as calculated with a 2-compartment model for both SD1 and SD2 were compared with those derived from FD by correlation (Pearson), regression (Passing–Bablok), deviation (Bland–Altman), and classification (area-under-the-receiver-operating characteristic curve) analyses. Simulations were performed to assess uncertainties due to statistical noise. Results: Strong correlation (r ≥ 0.75, P < 0.001) existed between all KRCs deduced from both SD1 and SD2, and from FD. Significant differences between KRCs were found only for FD-SD2 correlations in patient studies. K1 and k3 were reproducible to within approximately 6% and approximately 30% (FD-SD1; patients) and approximately 4% and approximately 75% (FD-SD2; animals). Area-under-the-receiver-operating characteristic curve values for classification of patient clusters as hypoxic, using a tumor-to-blood ratio greater than 1.2, were 0.91 (SD1) and 0.86 (SD2). The percentage SD in estimating K1 and k3 from 45-min shortened datasets due to noise was less than 1% and between 2% and 12%, respectively. Conclusion: Using single-session 45-min shortened 18F-fluoromisonidazole dPET datasets appears to be adequate for the identification of intratumor regions of hypoxia. However, k3 was significantly overestimated in the clinical cohort. Further studies are necessary to evaluate the clinical significance of differences between the results as calculated from full and shortened datasets.

[1]  F J Gilbert,et al.  Imaging tumour hypoxia with positron emission tomography , 2014, British Journal of Cancer.

[2]  J. Koutcher,et al.  Response of HT29 colorectal xenograft model to cediranib assessed with 18F‐fluoromisonidazole positron emission tomography, dynamic contrast‐enhanced and diffusion‐weighted MRI , 2013, NMR in biomedicine.

[3]  J. Petersen,et al.  Imaging hypoxia to improve radiotherapy outcome , 2012, Nature Reviews Clinical Oncology.

[4]  Yuka Yamamoto,et al.  Shortening the Duration of [18F]FDG PET Brain Examination for Diagnosis of Brain Glioma , 2011, Molecular Imaging and Biology.

[5]  J. Humm,et al.  Using an external gating signal to estimate noise in PET with an emphasis on tracer avid tumors , 2010, Physics in medicine and biology.

[6]  S. Jakobsen,et al.  Assessing hypoxia in animal tumor models based on pharmocokinetic analysis of dynamic FAZA PET , 2010, Acta oncologica.

[7]  John L. Humm,et al.  Pharmacokinetic Analysis of Hypoxia 18F-Fluoromisonidazole Dynamic PET in Head and Neck Cancer , 2010, Journal of Nuclear Medicine.

[8]  C. Ling,et al.  Immunohistochemical detection of changes in tumor hypoxia. , 2009, International journal of radiation oncology, biology, physics.

[9]  John L. Humm,et al.  Evaluation of a compartmental model for estimating tumor hypoxia via FMISO dynamic PET imaging , 2008, Physics in medicine and biology.

[10]  David L. Schwartz,et al.  Tumor Hypoxia Imaging with [F-18] Fluoromisonidazole Positron Emission Tomography in Head and Neck Cancer , 2006, Clinical Cancer Research.

[11]  Daniela Thorwarth,et al.  Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer , 2005, BMC Cancer.

[12]  Daniela Thorwarth,et al.  A kinetic model for dynamic [18F]-Fmiso PET data to analyse tumour hypoxia , 2005, Physics in medicine and biology.

[13]  Matthias Reimold,et al.  Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  Hiroyuki Okada,et al.  Short dynamic FDG-PET imaging protocol for patients with lung cancer , 2000, European Journal of Nuclear Medicine.

[15]  A. Evans,et al.  Correction for partial volume effects in PET: principle and validation. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  M. Dewhirst,et al.  Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. , 1997, International journal of radiation oncology, biology, physics.

[17]  T K Lewellen,et al.  Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. , 1996, International journal of radiation oncology, biology, physics.

[18]  M. Berridge,et al.  An efficient radiosynthesis of [18F]fluoromisonidazole. , 1993, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[19]  M. Zweig,et al.  Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. , 1993, Clinical chemistry.

[20]  F. Fazio,et al.  Errors Introduced by Tissue Heterogeneity in Estimation of Local Cerebral Glucose Utilization with Current Kinetic Models of the [18F]Fluorodeoxyglucose Method , 1992, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[21]  C S Patlak,et al.  The Influence of Tissue Heterogeneity on Results of Fitting Nonlinear Model Equations to Regional Tracer Uptake Curves: With an Application to Compartmental Models Used in Positron Emission Tomography , 1987, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[22]  D. Altman,et al.  STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.

[23]  Kewei Chen,et al.  Robust Clustering of Positron Emission Tomography Data , 2005 .

[24]  William H. Press,et al.  Numerical recipes in C , 2002 .

[25]  J. Overgaard,et al.  Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. , 1996, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[26]  S M Bentzen,et al.  Measurement of human tumour oxygenation status by a polarographic needle electrode. An analysis of inter- and intratumour heterogeneity. , 1994, Acta oncologica.

[27]  T W Griffin,et al.  Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. , 1992, International journal of radiation oncology, biology, physics.

[28]  W. Bablok,et al.  A New Biometrical Procedure for Testing the Equality of Measurements from Two Different Analytical Methods. Application of linear regression procedures for method comparison studies in Clinical Chemistry, Part I , 1983, Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie.